Since the inception of COVID-19 pandemic, there has been a challenging race for the development of precise diagnostic tests. Specific SARS-CoV-2 serological assays are the main tools used to estimate the rate of past infections or herd immunity in epidemiological studies, in addition to being helpful in guiding public health management policies. In this study, an in-house ELISA based on the construct of SARS-CoV-2 nucleocapsid (N) proteins, named rCoV2, rCoV4, and rCoV7, showed diagnostic performance for the detection of IgG antibodies. Sensitivity was evaluated in serum samples from patients with mild to moderate or severe COVID-19 infections, which were collected at different time points, while specificity was evaluated using pre-pandemic sera. In samples from mild to moderate cases obtained ≥16 days after the onset of symptoms, the sensitivities for rCoV2, rCoV4, and rCoV7 were 66.7%, 75%, and 77.8%, respectively. For samples from severe cases, the sensitivity was above 80% for all constructs. All proteins showed high specificity (94-98%). Overall, rCoV7 (C-terminus N-protein portion) showed better diagnostic performance, with 62.3% sensitivity in moderate and severe cases and 96.6% specificity. The SARS-CoV-2 ELISA using N-protein-based constructs could be a promisor tool for investigate the epidemiology of COVID-19 and monitor population-level serosurveillance.
1 January 2026 in Brazilian Archives of Biology and Technology
Bacillus toyonensis is a spore-forming bacterium widely used as a probiotic for animals and humans. It has been reported for its immunomodulatory properties, particularly in enhancing innate and acquired immune responses. One mechanism involved in immune modulation is the capacity of B. toyonensis to stimulate immune cells to produce cytokines. This study investigated the immunomodulatory effects of Bacillus toyonensis BCT-7112T on the macrophage-like cell line RAW 264.7. Cells were stimulated with B. toyonensis vegetative cells (live and killed), spores (viable and non-viable), DNA, and conditioned media for 24, 48, and 72 hours to evaluate proliferation. Additionally, cells were stimulated for 1, 8, and 24 hours and analyzed by qPCR for the transcription of Tnf-α, Il4, Il10, Nuclear Factor kappa Beta (Nfkβ), and Toll-like receptor 2 (Tlr-2). All B. toyonensis stimuli induced cell proliferation, with spores exhibiting the most significant increase (p < 0.05) across all time points. B. toyonensis also induced the transcription of Tnf-α, Il4, Il10 cytokines, Nfkβ, and Tlr-2, with the most pronounced effects (p<0.05) observed following stimulation with viable spores. Our findings suggest that B. toyonensis BCT-7112T has immunomodulatory effects through the activation of murine RAW 264.7 cells, supporting its potential as a model for studying probiotic immunomodulation.
The search for next-generation probiotics derived from the human gut microbiota has intensified due to their potential beneficial effects in modulating immunity and preventing diseases. Spore-forming bacteria are attractive probiotic candidates due to their functional traits and unique resilience, which offer high stability to commercial formulations. In this study, spore-forming bacteria isolated from human fecal samples were screened. Two strains, Bacillus spizizenii A1 and Priestia megaterium F6, were identified as non-hemolytic and not resistant to a panel of antibiotics relevant for spore formers. Both strains were characterized by using in silico and in vitro approaches, demonstrating relevant probiotic potential. The comparative analysis indicated B. spizizenii A1 as the most promising probiotic candidate due to the resistance of its spores to simulated gastric conditions and for its antioxidant, antimicrobial, and antibiofilm activities. Strain A1 combines a safety profile with functional probiotic traits and is therefore a strong candidate for further in vivo evaluation and future development as a next-generation probiotic.